MIAMI - HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), currently valued at $35.18 million, has announced its intention to acquire a majority stake in Neurospa ...
HOPE Therapeutics, wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a binding Letter of Intent, LOI, to acquire a majority interest in Neurospa TMS Holdings. Neurospa operates six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback